Alastair Burt
Alastair Burt
Verified email at adelaide.edu.au
Title
Cited by
Cited by
Year
The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD
P Angulo, JM Hui, G Marchesini, E Bugianesi, J George, GC Farrell, ...
Hepatology 45 (4), 846-854, 2007
19662007
Serum markers detect the presence of liver fibrosis: a cohort study
WMC Rosenberg, M Voelker, R Thiel, M Becka, A Burt, D Schuppan, ...
Gastroenterology 127 (6), 1704-1713, 2004
11812004
The natural history of nonalcoholic fatty liver: a follow‐up study
MR Teli, OFW James, AD Burt, MK Bennett, CP Day
Hepatology 22 (6), 1714-1719, 1995
11321995
Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers
IN Guha, J Parkes, P Roderick, D Chattopadhyay, R Cross, S Harris, ...
Hepatology 47 (2), 455-460, 2008
6822008
Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management
S McPherson, T Hardy, E Henderson, AD Burt, CP Day, QM Anstee
Journal of hepatology 62 (5), 1148-1155, 2015
5942015
EASL clinical practical guidelines: management of alcoholic liver disease
European Association For The Study Of The Liver
Journal of hepatology 57 (2), 399-420, 2012
5782012
Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease
S McPherson, SF Stewart, E Henderson, AD Burt, CP Day
Gut 59 (9), 1265-1269, 2010
5622010
Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver
MR Teli, CP Day, OFW James, AD Burt, MK Bennett
The Lancet 346 (8981), 987-990, 1995
5071995
Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major
NF Olivieri, GM Brittenham, CE McLaren, DM Templeton, RG Cameron, ...
New England Journal of Medicine 339 (7), 417-423, 1998
4601998
Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients
SU Nielsen, MF Bassendine, AD Burt, C Martin, W Pumeechockchai, ...
Journal of virology 80 (5), 2418-2428, 2006
4192006
Diagnosis and interpretation of steatosis and steatohepatitis.
AD Burt, A Mutton, CP Day
Seminars in diagnostic pathology 15 (4), 246-258, 1998
4081998
Liver fibrosis
K Wallace, AD Burt, MC Wright
Biochemical Journal 411 (1), 1-18, 2008
3852008
TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease
YL Liu, HL Reeves, AD Burt, D Tiniakos, S McPherson, JBS Leathart, ...
Nature communications 5 (1), 1-6, 2014
3712014
Elevated endotoxin levels in non-alcoholic fatty liver disease
AL Harte, NF da Silva, SJ Creely, KC McGee, T Billyard, ...
Journal of inflammation 7 (1), 15, 2010
3342010
Histologic spectrum of alcoholic liver disease
RNM MacSween, AD Burt
Seminars in liver disease 6 (03), 221-232, 1986
3041986
Nonalcoholic fatty liver disease
EM Brunt, VWS Wong, V Nobili, CP Day, S Sookoian, JJ Maher, ...
Nature reviews Disease primers 1 (1), 1-22, 2015
3012015
Pathology of the liver
RNM MacSween, PP Anthony, PJ Scheuer
Churchill Livingstone, 1979
2941979
Muir's textbook of pathology
D Levison, R Reid, AD Burt, DJ Harrison, S Fleming
CRC Press, 2012
2902012
Carriage of the PNPLA3 rs738409 C> G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma
YL Liu, GL Patman, JBS Leathart, AC Piguet, AD Burt, JF Dufour, CP Day, ...
Journal of hepatology 61 (1), 75-81, 2014
2852014
Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease
J Parkes, P Roderick, S Harris, C Day, D Mutimer, J Collier, M Lombard, ...
Gut 59 (9), 1245-1251, 2010
2802010
The system can't perform the operation now. Try again later.
Articles 1–20